RNXT
RenovoRx Inc
1.60$
+1.3%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | +2,511.6% | |
| – | – | – | -33.3% | -100.0% | – | – | |
| – | – | – | – | – | – | +1,751.2% | |
| – | -20.4% | +27.4% | +41.5% | +31.8% | +6.3% | +4.0% | |
| – | -9.0% | +221.8% | +114.6% | +1.4% | -12.9% | +41.1% | |
| – | -17.8% | +77.0% | +75.5% | +14.5% | -3.4% | +20.8% | |
| – | – | – | – | – | – | – | |
| – | – | +53.2% | -93.7% | +89.5% | +255.6% | – | |
| – | – | – | – | – | – | – | |
| – | – | +31.5% | -115.3% | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.